The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | LIMBER-104 update: zilurgisertib as monotherapy or with ruxolitinib in patients with MF and anemia
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an update on the LIMBER-104 (NCT04455841) trial investigating zilurgisertib as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis (MF). Dr Bose highlights that hepcidin levels decrease in a dose-proportional manner with zilurgisertib administration. In addition, anemia responses have been observed in non-transfusion-dependent patients in both evaluable arms. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
